TD Cowen Maintains Buy on Surgery Partners, Raises Price Target to $19
TD Cowen analyst Ryan Langston maintains Surgery Partners (NASDAQ:SGRY) with a Buy and raises the price target from $17 to $19.
Read original at benzingaStocks · News reference
Surgery Partners Monetizes Idaho Assets As It Chases Faster Growth
Surgery Partners rises after agreeing to sell Idaho Falls hospital stakes for $795 million while reaffirming its 2026 outlook
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 24, 2026, 4:56 PM
- Checked
- Jul 24, 2026, 4:56 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
RBC Capital Maintains Outperform on Surgery Partners, Lowers Price Target to $19
RBC Capital analyst Ben Hendrix maintains Surgery Partners (NASDAQ:SGRY) with a Outperform and lowers the price target from $20 to $19.
Read original at benzingaCantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $18 Price Target
Cantor Fitzgerald analyst Sarah James reiterates Surgery Partners (NASDAQ:SGRY) with a Overweight and maintains $18 price target.
Read original at benzinga8-K filing — Surgery Partners, Inc. (SGRY)
Filed: 2026-08-10 AccNo: 0001638833-26-000074 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar